Jan 25 (Reuters) - ALLIGATOR BIOSCIENCE AB:
* ALLIGATOR BIOSCIENCE CONTRACTS THERADEX ONCOLOGY AS CLINICAL CRO FOR THE UPCOMING ATOR-1015 PHASE I STUDY
* STUDY IS EXPECTED TO COMMENCE IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
 